Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma

BACKGROUND: Fatigue is a common adverse event during lenvatinib treatment in patients with hepatocellular carcinoma. One mechanism contributing to development of fatigue might involve abnormal adenosine triphosphate synthesis that is caused by carnitine deficiency. To address this possibility, we ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Okubo, Hironao, Ando, Hitoshi, Ishizuka, Kei, Kitagawa, Ryuta, Okubo, Shoki, Saito, Hiroaki, Kokubu, Shigehiro, Miyazaki, Akihisa, Ikejima, Kenichi, Shiina, Shuichiro, Nagahara, Akihito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053710/
https://www.ncbi.nlm.nih.gov/pubmed/32126131
http://dx.doi.org/10.1371/journal.pone.0229772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053710/
https://www.ncbi.nlm.nih.gov/pubmed/32126131
http://dx.doi.org/10.1371/journal.pone.0229772

Ejemplares similares